All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Key highlights from a descriptive analysis of the POLARIX trial
Featured
Bookmark this article
During the 17th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub spoke with Charles Herbaux, University of Montpellier, Montpellier, FR. We asked, What are the key highlights from the descriptive analysis of the POLARIX trial (NCT03274492) in patients with diffuse large B-cell lymphoma (DLBCL).
Key highlights from a descriptive analysis of the POLARIX trial
POLARIX is a phase III trial investigating R-CHOP (cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine) vs R-CHP (cyclophosphamide, doxorubicin, prednisone and rituximab) in combination with polatuzumab vedotin. Herbaux describes key results of the ad hoc analysis evaluating (1) the cause of death and prognosis of patients with primary refractory disease and (2) the prognosis of patients who are progression‐free at 24 m (PFS24) after 1L treatment.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox